S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:ORGS

Orgenesis - ORGS Stock Forecast, Price & News

$1.31
-0.06 (-4.38%)
(As of 03/28/2023 04:17 PM ET)
Add
Compare
Today's Range
$1.30
▼
$1.39
50-Day Range
$1.24
▼
$2.59
52-Week Range
$1.13
▼
$4.04
Volume
40,136 shs
Average Volume
76,189 shs
Market Capitalization
$36.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Orgenesis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
358.0% Upside
$6.00 Price Target
Short Interest
Healthy
1.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.49
Upright™ Environmental Score
News Sentiment
0.49mentions of Orgenesis in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

380th out of 1,002 stocks

Pharmaceutical Preparations Industry

169th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

ORGS stock logo

About Orgenesis (NASDAQ:ORGS) Stock

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

March 25, 2023 | americanbankingnews.com
Orgenesis' (ORGS) Buy Rating Reaffirmed at Benchmark
March 24, 2023 | finance.yahoo.com
Orgenesis Inc. (NASDAQ:ORGS) Q4 2022 Earnings Call Transcript
March 28, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
March 23, 2023 | benzinga.com
Orgenesis Stock (NASDAQ:ORGS), Guidance and Forecast
March 21, 2023 | finanznachrichten.de
Orgenesis Inc.: Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022
March 21, 2023 | finance.yahoo.com
Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022
March 17, 2023 | finance.yahoo.com
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
March 16, 2023 | finance.yahoo.com
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California
March 28, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
February 27, 2023 | finance.yahoo.com
Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering
February 23, 2023 | finance.yahoo.com
Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering
January 4, 2023 | finance.yahoo.com
Investors in Orgenesis (NASDAQ:ORGS) have unfortunately lost 73% over the last five years
December 22, 2022 | msn.com
Orgenesis's Return On Capital Employed Insights
December 20, 2022 | finance.yahoo.com
Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model
November 23, 2022 | 247wallst.com
New Dimensions Trading Discloses Large Position in ORGS / Orgenesis
November 16, 2022 | finance.yahoo.com
Orgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
November 13, 2022 | seekingalpha.com
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript
November 12, 2022 | finance.yahoo.com
Loss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-Term
November 11, 2022 | finanznachrichten.de
Orgenesis Inc.: Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022
November 10, 2022 | finance.yahoo.com
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call
November 10, 2022 | finance.yahoo.com
Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022
November 7, 2022 | msn.com
EXCLUSIVE: Orgenesis' Subsidiary Secures $50M Investment To Accelerate Point-of-Care Services Growth
November 7, 2022 | finance.yahoo.com
Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services
October 28, 2022 | finance.yahoo.com
Oracle Helps Healthcare Organizations Create Patient-Centered Supply Chains
September 19, 2022 | reuters.com
ORGS.OQ - Orgenesis Inc | Stock Price & Latest News | Reuters
September 10, 2022 | nasdaq.com
Shareholders in Orgenesis (NASDAQ:ORGS) are in the red if they invested five years ago
August 16, 2022 | seekingalpha.com
Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript
See More Headlines
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Company Calendar

Last Earnings
11/04/2021
Today
3/28/2023
Next Earnings (Estimated)
5/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORGS
CUSIP
N/A
CIK
1460602
Web
www.orgenesis.com
Phone
(480) 659-6404
Fax
N/A
Employees
111
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+338.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,890,000.00
Net Margins
-33.80%
Pretax Margin
-33.20%
Return on Equity
-38.65%
Return on Assets
-17.21%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
2.91
Quick Ratio
2.90

Sales & Book Value

Annual Sales
$36.03 million
Price / Sales
1.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
1.20

Miscellaneous

Outstanding Shares
27,490,000
Free Float
25,379,000
Market Cap
$37.66 million
Optionable
Not Optionable
Beta
0.89

Social Links


Key Executives

  • Vered Caplan
    Chairman, President & Chief Executive Officer
  • Neil Reithinger
    Chief Financial Officer, Secretary & Treasurer
  • Sarah Ferber
    Chief Scientific Officer
  • Heiko von der Leyen
    Medical Director
  • Efrat Assa-Kunik
    Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ORGS Stock - Frequently Asked Questions

Should I buy or sell Orgenesis stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORGS shares.
View ORGS analyst ratings or view top-rated stocks.

What is Orgenesis' stock price forecast for 2023?

1 brokerages have issued twelve-month price objectives for Orgenesis' stock. Their ORGS share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 338.0% from the stock's current price.
View analysts price targets for ORGS or view top-rated stocks among Wall Street analysts.

How have ORGS shares performed in 2023?

Orgenesis' stock was trading at $1.95 at the beginning of the year. Since then, ORGS shares have decreased by 29.7% and is now trading at $1.37.
View the best growth stocks for 2023 here.

Are investors shorting Orgenesis?

Orgenesis saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 304,800 shares, a decrease of 19.1% from the February 28th total of 376,800 shares. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is currently 4.3 days. Approximately 1.3% of the shares of the stock are short sold.
View Orgenesis' Short Interest.

When is Orgenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023.
View our ORGS earnings forecast.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its earnings results on Thursday, November, 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.39. The company earned $7.61 million during the quarter. Orgenesis had a negative net margin of 33.80% and a negative trailing twelve-month return on equity of 38.65%.

What is Orgenesis' stock symbol?

Orgenesis trades on the NASDAQ under the ticker symbol "ORGS."

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.81%), Dimensional Fund Advisors LP (0.14%), Chapin Davis Inc. (0.08%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $1.37.

How much money does Orgenesis make?

Orgenesis (NASDAQ:ORGS) has a market capitalization of $37.66 million and generates $36.03 million in revenue each year. The company earns $-14,890,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does Orgenesis have?

The company employs 111 workers across the globe.

Does Orgenesis have any subsidiaries?
The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.
Read More
How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for the company is www.orgenesis.com. The company can be reached via phone at (480) 659-6404 or via email at orgs@crescendo-ir.com.

This page (NASDAQ:ORGS) was last updated on 3/28/2023 by MarketBeat.com Staff